Richard O Chen, MD
Dermatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 11
- 3 carriers
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
11 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Chen’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
11 of 11 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A105615 · Current
Licensed to practise in California · since 2008 · expires 2028-08-31 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$16,494
Medicare paid this office $16,494 for 118 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 69 | $4,953 | $56 |
| Return visit (30+ min) | 42 | $3,682 | $75 |
| Destruction of precancer skin growth, 1 growth | 50 | $3,018 | $45 |
| Destruction of skin growth, 1-14 growths | 27 | $2,146 | $65 |
| Short return visit | 18 | $680 | $30 |
See all 7 services
| Short return visit (20+ min) | 69 | $4,953 | $56 |
| Return visit (30+ min) | 42 | $3,682 | $75 |
| Destruction of precancer skin growth, 1 growth | 50 | $3,018 | $45 |
| Destruction of skin growth, 1-14 growths | 27 | $2,146 | $65 |
| Short return visit | 18 | $680 | $30 |
| Biopsy of related skin growth, first growth | 22 | $459 | $19 |
| Destruction of precancer skin growth, 2-14 growths | 40 | $422 | $2 |
Procedures Medicare counted
| Removal of skin lesions | 187 | More than 79% of doctors who do this |
| Skin biopsy | 36 | More than 67% of doctors who do this |
Who their Medicare patients are
118 Original Medicare patients in 2024. Average age 74 · Women 53% · Also on Medicaid 16% · Health risk score 1.29. Sicker patients than 9 in 10 peers; the typical dermatology clinician is at 1.01.
Conditions among them: High blood pressure 56% · Diabetes 25% · Cancer 25% · Coronary heart disease 23% · Chronic kidney disease 20% · Atrial fibrillation 14% · Heart failure 11% · Depression 11%.
The office billed $71,388, Medicare allowed $22,830 and paid $16,494; for 557 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 118 | 557 | 74 | 1.29 | $71,388 | $16,494 |
| 2023 | 95 | 454 | 74 | 1.11 | $51,897 | $14,098 |
| 2022 | 89 | 420 | 74 | 1.01 | $46,167 | $11,901 |
| 2021 | 89 | 377 | 76 | 1.11 | $37,690 | $10,234 |
| 2020 | 79 | 272 | 74 | 1.24 | $35,062 | $7,347 |
| 2019 | 81 | 326 | 73 | 1.36 | $26,526 | $8,104 |
| 2018 | 92 | 366 | 72 | 1.56 | $28,987 | $9,033 |
| 2017 | 80 | 391 | 73 | 0.98 | $31,094 | $8,958 |
| 2016 | 90 | 385 | 72 | 1.35 | $33,490 | $9,732 |
| 2015 | 90 | 371 | 72 | 1.18 | $34,017 | $8,843 |
| 2014 | 80 | 440 | 71 | 1.18 | $38,409 | $9,246 |
| 2013 | 75 | 445 | 70 | 1.14 | $35,743 | $9,800 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Short return visit (20+ min) | 63 | $4,445 | $54 |
| Destruction of precancer skin growth, 1 growth | 46 | $3,054 | $46 |
| Return visit (30+ min) | 29 | $2,825 | $86 |
| Destruction of skin growth, 1-14 growths | 24 | $1,695 | $63 |
| Short return visit | 14 | $643 | $32 |
| Biopsy of related skin growth, first growth | 19 | $442 | $21 |
| Destruction of precancer skin growth, 2-14 growths | 41 | $331 | $2 |
2022: 6 services
| Short return visit (20+ min) | 69 | $4,379 | $47 |
| Return visit (30+ min) | 23 | $2,319 | $80 |
| Destruction of precancer skin growth, 1 growth | 39 | $2,153 | $39 |
| Destruction of skin growth, 1-14 growths | 17 | $1,346 | $64 |
| Biopsy of related skin growth, first growth | 12 | $307 | $24 |
| Destruction of precancer skin growth, 2-14 growths | 31 | $274 | $1 |
2021: 6 services
| Short return visit (20+ min) | 79 | $5,233 | $53 |
| Destruction of precancer skin growth, 1 growth | 43 | $2,220 | $45 |
| Destruction of skin growth, 1-14 growths | 20 | $1,075 | $51 |
| Biopsy of related skin growth, first growth | 18 | $454 | $25 |
| Short return visit | 11 | $399 | $29 |
| Destruction of precancer skin growth, 2-14 growths | 38 | $316 | $2 |
2020: 5 services
| Short return visit (20+ min) | 54 | $2,713 | $39 |
| Destruction of precancer skin growth, 1 growth | 31 | $1,850 | $49 |
| Short return visit | 22 | $587 | $18 |
| Biopsy of related skin growth, first growth | 14 | $310 | $19 |
| Destruction of precancer skin growth, 2-14 growths | 24 | $146 | $2 |
2019: 5 services
| Short return visit (20+ min) | 60 | $3,200 | $42 |
| Destruction of precancer skin growth, 1 growth | 25 | $1,396 | $44 |
| Short return visit | 14 | $457 | $22 |
| Biopsy of related skin growth, first growth | 12 | $438 | $27 |
| Destruction of precancer skin growth, 2-14 growths | 22 | $218 | $2 |
2018: 6 services
| Short return visit (20+ min) | 65 | $3,484 | $38 |
| Destruction of precancer skin growth, 1 growth | 33 | $1,888 | $40 |
| New patient visit (30+ min) | 14 | $849 | $61 |
| Biopsy of single growth of skin and/or tissue | 21 | $642 | $29 |
| Short return visit | 21 | $607 | $20 |
| Destruction of precancer skin growth, 2-14 growths | 24 | $198 | $2 |
2017: 6 services
| Short return visit (20+ min) | 59 | $3,421 | $41 |
| Destruction of precancer skin growth, 1 growth | 34 | $1,986 | $43 |
| Destruction of skin growth, 1-14 growths | 12 | $887 | $49 |
| Short return visit | 20 | $633 | $20 |
| Biopsy of single growth of skin and/or tissue | 13 | $400 | $31 |
| Destruction of precancer skin growth, 2-14 growths | 28 | $333 | $2 |
2016: 5 services
| Short return visit (20+ min) | 71 | $4,030 | $42 |
| Destruction of precancer skin growth, 1 growth | 43 | $2,667 | $46 |
| Short return visit | 28 | $775 | $20 |
| Biopsy of single growth of skin and/or tissue | 12 | $421 | $35 |
| Destruction of precancer skin growth, 2-14 growths | 32 | $275 | $2 |
2015: 5 services
| Short return visit (20+ min) | 70 | $4,024 | $42 |
| Destruction of precancer skin growth, 1 growth | 35 | $1,864 | $41 |
| Biopsy of single growth of skin and/or tissue | 16 | $581 | $34 |
| Short return visit | 21 | $373 | $16 |
| Destruction of precancer skin growth, 2-14 growths | 25 | $272 | $2 |
2014: 7 services
| Short return visit (20+ min) | 52 | $2,687 | $40 |
| Destruction of precancer skin growth, 1 growth | 38 | $2,315 | $41 |
| Return visit (30+ min) | 16 | $1,185 | $56 |
| New patient visit (30+ min) | 16 | $946 | $59 |
| Destruction of precancer skin growth, 2-14 growths | 33 | $460 | $2 |
| Biopsy of single growth of skin and/or tissue | 12 | $421 | $35 |
| Short return visit | 16 | $401 | $22 |
2013: 6 services
| Short return visit (20+ min) | 53 | $3,515 | $39 |
| Destruction of precancer skin growth, 1 growth | 24 | $1,957 | $47 |
| Destruction of precancer skin growth, 2-14 growths | 20 | $826 | $4 |
| Biopsy of single growth of skin and/or tissue | 21 | $655 | $28 |
| New patient visit (30+ min) | 11 | $597 | $54 |
| Short return visit | 18 | $474 | $19 |
Drugs they prescribed that Part D paid
$289,519
Pharmacies billed $289,519 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 246) in 2024. At or below the middle of the specialty; the typical dermatology clinician is at 0%.
213 generic and 33 brand-name prescriptions · $289,519 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Taltz | 13 | $86,033 | $6,618 |
| Desonide | 32 | $2,863 | $89 |
| Fluocinonide | 13 | $796 | $61 |
| Ketoconazole | 49 | $639 | $13 |
| Metronidazole | 12 | $552 | $46 |
See all 7 drugs
| Taltz | 13 | $86,033 | $6,618 |
| Desonide | 32 | $2,863 | $89 |
| Fluocinonide | 13 | $796 | $61 |
| Ketoconazole | 49 | $639 | $13 |
| Metronidazole | 12 | $552 | $46 |
| Triamcinolone Acetonide | 40 | $501 | $13 |
| Clobetasol Propionate | 12 | $473 | $39 |
Year by year
| 2024 | 246 | 78 | 0% (0) | 13% | $289,519 |
| 2023 | 265 | 63 | 0% (0) | 12% | $230,067 |
| 2022 | 228 | 52 | 0% (0) | 11% | $176,225 |
| 2021 | 157 | 53 | 0% (0) | None | $40,323 |
| 2020 | 137 | 46 | 0% (0) | None | $22,176 |
| 2019 | 134 | 51 | 0% (0) | 13% | $43,558 |
| 2018 | 123 | 37 | 0% (0) | 23% | $57,446 |
| 2017 | 123 | 38 | 0% (0) | 25% | $48,499 |
| 2016 | 180 | 56 | None | 14% | $49,538 |
| 2015 | 257 | 59 | 0% (0) | 11% | $25,475 |
| 2014 | 217 | 49 | 0% (0) | 15% | $18,320 |
| 2013 | 146 | 38 | 0% (0) | 18% | $9,373 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 8 drugs
| Taltz | 13 | $92,476 | $7,114 |
| Desonide | 18 | $2,007 | $111 |
| Fluocinonide | 30 | $1,906 | $64 |
| Clobetasol Propionate | 17 | $1,034 | $61 |
| Fluorouracil | 11 | $844 | $77 |
| Ketoconazole | 42 | $745 | $18 |
| Triamcinolone Acetonide | 40 | $447 | $11 |
| Minoxidil | 12 | $130 | $11 |
2022: 6 drugs
| Taltz | 13 | $88,073 | $6,775 |
| Fluocinonide | 40 | $2,832 | $71 |
| Ketoconazole | 52 | $900 | $17 |
| Clobetasol Propionate | 13 | $837 | $64 |
| Triamcinolone Acetonide | 27 | $438 | $16 |
| Hydrocortisone | 13 | $213 | $16 |
2021: 4 drugs
| Fluocinonide | 21 | $1,024 | $49 |
| Ketoconazole | 28 | $611 | $22 |
| Triamcinolone Acetonide | 22 | $398 | $18 |
| Ciclopirox | 12 | $314 | $26 |
2020: 5 drugs
| Ketoconazole | 29 | $730 | $25 |
| Methotrexate | 13 | $641 | $49 |
| Fluocinonide | 12 | $547 | $46 |
| Clobetasol Propionate | 11 | $489 | $44 |
| Triamcinolone Acetonide | 23 | $327 | $14 |
2019: 3 drugs
| Fluocinonide | 20 | $1,129 | $56 |
| Ketoconazole | 32 | $554 | $17 |
| Triamcinolone Acetonide | 20 | $397 | $20 |
2018: 2 drugs
| Ketoconazole | 30 | $516 | $17 |
| Triamcinolone Acetonide | 15 | $298 | $20 |
2017: 3 drugs
| Fluocinonide | 21 | $1,752 | $83 |
| Ketoconazole | 24 | $546 | $23 |
| Triamcinolone Acetonide | 15 | $290 | $19 |
2016: 5 drugs
| Clobetasol Propionate | 27 | $6,718 | $249 |
| Fluocinonide | 35 | $3,677 | $105 |
| Doxycycline Hyclate | 11 | $3,202 | $291 |
| Ketoconazole | 22 | $318 | $14 |
| Triamcinolone Acetonide | 13 | $287 | $22 |
2015: 7 drugs
| Fluocinonide | 60 | $7,241 | $121 |
| Clobetasol Propionate | 19 | $5,161 | $272 |
| Desonide | 17 | $1,714 | $101 |
| Methotrexate | 15 | $686 | $46 |
| Hydroxyzine | 17 | $658 | $39 |
| Triamcinolone Acetonide | 25 | $411 | $16 |
| Ketoconazole | 16 | $213 | $13 |
2014: 4 drugs
| Clobetasol Propionate | 33 | $4,871 | $148 |
| Fluocinonide | 44 | $2,750 | $62 |
| Desonide | 20 | $2,222 | $111 |
| Ketoconazole | 23 | $394 | $17 |
2013: 6 drugs
| Clobetasol Propionate | 23 | $1,461 | $64 |
| Methotrexate | 12 | $1,078 | $90 |
| Fluocinonide | 16 | $974 | $61 |
| Hydroxyzine | 11 | $318 | $29 |
| Ketoconazole | 12 | $313 | $26 |
| Prednisone | 12 | $112 | $9 |
Money from drug and device companies
$31 in 2023
| 2023 | 1 | 2 | None | $31 |
| 2020 | 1 | 1 | None | $225 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Pfizer | Cibinqo | $31 | 2 payments
|
See all 2 published payments
| Pfizer | Education · 2023-05-10 | Cibinqo | $15 |
| Pfizer | Education · 2023-04-12 | Cibinqo | $15 |
See earlier years (2020)
2020: $225
| E.R. Squibb & Sons L.L.C. | None | $225 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1598929069
- Licence
- CA A105615California A105615: Current · expires 2028-08-31
- Trained
- Stanford University School of Medicine, 2007
- Group
- Stanford Health Care
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 207N00000X (207N00000X)
- Mailing address
- 450 Broadway Ave, Dept of Dermatology, Pavillion C, 2nd Floor, Redwood City, CA, 94063
- NPI first listed
- 2008-07-15
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 450 Broadway Ave, Redwood City, CA, 94063